Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peritoneal Neoplasms
Conditions
Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis
Trial Timeline
Sep 1, 2005 → Sep 1, 2008
NCT ID
NCT00332696About Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + Placebo is a phase 2 stage product being developed by Novartis for Peritoneal Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00332696. Target conditions include Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00332696 | Phase 2 | Completed |
Competing Products
20 competing products in Peritoneal Neoplasms